AIM-HI Accelerator Fund (Aim-Hi Accelerator Fund)

AIM-HI Accelerator Fund

Purpose: A disruptive funding model designed to accelerate cancer innovations from laboratory bench to patients at their bedside, bridging the "valley of death" between basic research breakthroughs and clinical application.

Funding Model:

• Harnesses the power of business leaders and philanthropists in the US and worldwide
• Utilizes venture philanthropy and impact investments
• Creates an evergreen model of funding innovations and their commercialization
• Focuses on measurable outcomes

Focus Areas:

• Early-stage cancer innovations waiting for commercialization
• Prevention, treatment and care innovations
• Genomic-based research applications
• Diagnostics and prevention strategies
• Next-generation cancer therapies

Problem Addressed:

• Many breakthroughs in cancer research remain confined to laboratories and unable to reach clinics
• Early-stage areas are extremely risky with high fail rates
• Traditional venture capitalists and large pharmaceutical companies unwilling to take these risks
• Need for paradigm shift in accelerating cancer innovation to patient benefit

Scope: United States and worldwide

Paradigm:

• Moves beyond traditional NFCR focus on basic science to include translational research
• Aims to translate laboratory discoveries into FDA-approved therapies
• Emphasis on getting innovations into clinics faster

Background: Launched as response to fruition point of past decades' advances in genomic-based research, with many innovations ready for commercialization but lacking adequate funding mechanisms.

Contact:

• National Foundation for Cancer Research
• Phone: 1-800-321-CURE (2873)
• Email: info@nfcr.org
• Address: 5515 Security Lane, Suite 1105, Rockville, MD 20852